Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00542 ...
Drug Name Benazepril
Molecular Weight 424.4895
Molecular Formula C24H28N2O5
CAS Number 86541-75-5
SMILES [H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC
External Links
DRUGBANK DB00542
PubChem Compound 5362124
PDR 1006
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Boiling Point 691.2 ℃ 691.2 ℃ http://www.chemspider.com/Chemical-Structure.4514935.html
Melting Point 148.5 ℃ 148.5 ℃ http://www.chemspider.com/Chemical-Structure.4514935.html
Water Solubility 19000.0 mg/L 19 mg/ml http://www.chemspider.com/Chemical-Structure.4514935.html

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 3.5 % 3-4 % PO, oral; horse; DRUGBANK
Bioavailability 37.0 % 37 % PO, oral; DRUGBANK
Bioavailability 18.0 % ≥18 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 127.3 ng/ml ~300 nM Oral single dose; adults; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 212.2 ng/ml ~500 nM Oral single dose; Active metabolite; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 0.75 h 0.5-1 h PO, oral; DRUGBANK
T Max 1.5 h 1.5 h PO, oral; different study; DRUGBANK
T Max 0.75 h 0.5-1.0 h Oral single dose; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 1.3 h 1-1.5 h Oral single dose; Active metabolite; adults; normal,healthy; The Pharmacological Basis of Therapeutics
Clearance 129.0 L 129±30.0 L DRUGBANK
Clearance 0.0210 L/h/kg 0.3-0.4 ml/min/kg apparent clearance; The Pharmacological Basis of Therapeutics
Volume of Distribution 203.0 L 203±69.9 L DRUGBANK
Volume of Distribution 0.12 L/kg 0.12 L/kg Apparent volume of distribution; The Pharmacological Basis of Therapeutics
Half-life 2.7 h 2.7±8.5 h DRUGBANK
Half-life 22.3 h 22.3±9.2 h Active metabolite; DRUGBANK
Half-life 10.5 h 10-11 h DRUGBANK
Half-life 0.70 h 0.7 h Age ↑ ; The Pharmacological Basis of Therapeutics
Half-life 10.5 h 10-11 h Active metabolite; Age ↑ ; The Pharmacological Basis of Therapeutics
Half-life 22.0 h ~22 h terminal half-life; Active metabolite; The Pharmacological Basis of Therapeutics
Eliminate Route 11.5 % ~11-12 % Bile excretion; DRUGBANK
Eliminate Route 1.0 % <1 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Eliminate Route 18.0 % 18 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 96.7 % 96.7 % DRUGBANK
Protein Binding 97.0 % 97 % Unchanged drug; Elderly → ;Hepatitis, Hep → ; The Pharmacological Basis of Therapeutics
Protein Binding 95.0 % 95 % Active metabolite; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 0.6 mg/kg/day 0.6 mg/kg/day PO, oral Lotensin benazepril hydrochloride PDR
Max dose for children 40.0 mg/day 40 mg/day PO, oral Lotensin benazepril hydrochloride PDR
Max dose for adolescents 0.6 mg/kg/day 0.6 mg/kg/day PO, oral Lotensin benazepril hydrochloride PDR
Max dose for adolescents 40.0 mg/day 40 mg/day PO, oral Lotensin benazepril hydrochloride PDR
Max dose for adults 80.0 mg/day 80 mg/day PO, oral Lotensin benazepril hydrochloride PDR
Max dose for adults 20.0 mg/day 20 mg/day PO, oral Lotensin benazepril hydrochloride PDR
Max dose for geriatric 80.0 mg/day 80 mg/day PO, oral Lotensin benazepril hydrochloride PDR
Max dose for geriatric 20.0 mg/day 20 mg/day PO, oral Lotensin benazepril hydrochloride PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1